NCT03325101 2025-06-12
Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
Mayo Clinic
Phase 1/2 Terminated
Mayo Clinic
Boston Scientific Corporation
Alliance for Clinical Trials in Oncology
Washington University School of Medicine